(Circulation. 1996;94:2982-2985.)
© 1996 American Heart Association, Inc.
Articles |
Estrogens for Prevention of Coronary Heart Disease
Putting the Brakes on the Bandwagon
the Office of Disease Prevention, National Institutes of Health, Bethesda, Md.
Correspondence to Dr Jacques E. Rossouw, Women's Health Initiative, National Institutes of Health, Federal Bldg, Room 6A09, Bethesda, MD 20892. E-mail Jacques Rossouw@NIH.GOV.
Key Words: myocardial infarction • hormones • prevention • women
 |
Introduction |
|---|
Eighty-two percent of 1383 cardiologists, internists, family doctors, and general practitioners surveyed by the National Heart, Lung, and Blood Institute (NHLBI) reported that they prescribe hormone replacement therapy (HRT). Of those who prescribe it, 93% do so for relief of menopausal symptoms and 91% for osteoporosis. These are proven and accepted indications for estrogen replacement therapy. However, 41% also prescribe it for high blood cholesterol, and 66% prescribe it for coronary heart disease. These are not proven indications and should not be accepted as such until unequivocal clinical trial data are available. Why, then, have so many medical practitioners climbed aboard the HRT bandwagon? That bandwagon is clearly rolling, as anyone who reads newspapers or magazines, watches television, or talks to colleagues can attest. The bandwagon appears to be picking up in speed and volume. The putative benefits of HRT are being trumpeted to postmenopausal women, with only transient muting for reports of possible adverse effects.
|
Background |
|---|
A short history of HRT is instructive. The use of postmenopausal estrogens first gathered momentum during the sixties under the banner of "feminine forever." The promise to women that estrogens would hold back the ravages of time went unfulfilled, and instead they learned that they were being put at increased risk of endometrial cancer.1 Other disturbing news emerged: estrogens increased the risk of coronary heart disease (CHD) in men, and oral contraceptives increased the risk of CHD and stroke in middle-aged women.2 3 Result: from the midseventies onward, estrogen use declined precipitously.4 Better news started
This article has been cited by other articles:
 |
|
 |
|
  A. P. Miller, Y.-F. Chen, D. Xing, W. Feng, and S. Oparil Hormone Replacement Therapy and Inflammation: Interactions in Cardiovascular Disease Hypertension, October 1, 2003; 42(4): 657 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Waters Estrogen therapy for unstable angina: Another bump for the bandwagon J. Am. Coll. Cardiol., January 16, 2002; 39(2): 238 - 240. [Full Text] [PDF]
|
|
|
|
 |
|
 P.R.R. Gangula, P. Lanlua, S. Wimalawansa, S. Supowit, D. DiPette, and C. Yallampalli Regulation of Calcitonin Gene-Related Peptide Expression in Dorsal Root Ganglia of Rats by Female Sex Steroid Hormones Biol Reprod, April 1, 2000; 62(4): 1033 - 1039. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. A. Grover Estrogen replacement for women with cardiovascular disease: Why don't physicians and patients follow the guidelines? Can. Med. Assoc. J., July 1, 1999; 161(1): 42 - 43. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L Kuroski de Bold Estrogen, natriuretic peptides and the renin-angiotensin system Cardiovasc Res, March 1, 1999; 41(3): 524 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vazquez, J. C. Rodriguez-Manzaneque, J. P. Lydon, D. P. Edwards, B. W. O'Malley, and M. L. Iruela-Arispe Progesterone Regulates Proliferation of Endothelial Cells J. Biol. Chem., January 22, 1999; 274(4): 2185 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oparil Hormones and Vasoprotection Hypertension, January 1, 1999; 33(1): 170 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, E. Vittinghoff, and for the Heart and Estrogen/progestin Replacement S Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women JAMA, August 19, 1998; 280(7): 605 - 613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Vogel and M. C. Corretti Estrogens, Progestins, and Heart Disease : Can Endothelial Function Divine the Benefit? Circulation, April 7, 1998; 97(13): 1223 - 1226. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Matsubara, M. Murata, K. Kawano, T. Zama, N. Aoki, H. Yoshino, G. Watanabe, K. Ishikawa, and Y. Ikeda Genotype Distribution of Estrogen Receptor Polymorphisms in Men and Postmenopausal Women From Healthy and Coronary Populations and Its Relation to Serum Lipid Levels Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 3006 - 3012. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Sullivan Estrogen Replacement Circulation, December 1, 1996; 94(11): 2699 - 2702. [Full Text]
|
|